VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Q: When is the next results date for Vivimed Labs Ltd?

The next results date for Vivimed Labs Ltd is scheduled for 13 February 2026.

Q: Should I buy, sell or hold Vivimed Labs Ltd?

Based on the current situation of Vivimed Labs Ltd, it is advisable to consider a strong sell position. The company has not declared any results in the last six months, which raises significant concerns about its operational transparency and financial health. Additionally, the high Debt to EBITDA ratio of 12.57 times indicates a low ability to service its debt, which is a critical red flag for investors. The Return on Equity (ROE) of just 1.75% suggests that the company is struggling to generate profits relative to shareholders' funds.Recent financial results have also been troubling, with a negative profit after tax of Rs -281.57 crore, reflecting a decline of 34.93%. The debt-equity ratio is alarmingly high at 9.60 times, and the debtors turnover ratio is at its lowest point of 2.44 times, indicating inefficiencies in managing receivables.Given these factors, including the lack of recent financial disclosures and the significant drop in profits over the past year, the stock appears to be trading at a risky valuation. Therefore, it would be prudent to consider selling your shares in Vivimed Labs Ltd at this time.

Q: Why is Vivimed Labs Ltd falling/rising?

As of 10-Feb, Vivimed Labs Ltd's stock price is falling, currently at 7.24, reflecting a change of -0.29 or -3.85%. This decline is evident in the stock's performance over various periods, with a significant drop of -30.98% over the past month and a staggering -58.93% year-to-date. In comparison, the benchmark Sensex has shown positive returns in these periods, with a +0.83% increase over the last month and a -1.11% year-to-date.Today's performance indicates that Vivimed Labs Ltd has underperformed its sector by -3.81%. Additionally, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 169.38% against the 5-day average, the overall market sentiment appears negative. This combination of underperformance relative to the sector and benchmarks, along with trading below moving averages, contributes to the stock's decline.

Upcoming Result: Vivimed Labs. will declare its result soon on 13 Feb 2026

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

10.13 lacs (59.79%) Volume

Shareholding (Sep 2025)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.77%

When is the next results date for Vivimed Labs Ltd?

03-Feb-2026

The next results date for Vivimed Labs Ltd is 13 February 2026.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

06-Feb-2026

Why is Vivimed Labs Ltd falling/rising?

10-Feb-2026

As of 10-Feb, Vivimed Labs Ltd's stock price is at 7.24, down 3.85%, with significant declines of -30.98% over the past month and -58.93% year-to-date, indicating underperformance compared to the Sensex and bearish trading trends. Despite increased investor participation, the overall market sentiment remains negative.

View full answer

Which are the latest news on Vivimed Labs.?

11-Feb-2026

Vivimed Labs Ltd Shares Plunge to Lower Circuit Amid Heavy Selling Pressure
Vivimed Labs Ltd Hits Upper Circuit Amid Strong Buying Pressure

Compare Vivimed Labs. with Similar Stocks

Dr Reddy's Labs Guj. Inject(Ker)Torrent Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Low ability to service debt as the company has a high Debt to EBITDA ratio of 12.57 times
The company has been able to generate a Return on Equity (avg) of 1.75% signifying low profitability per unit of shareholders funds

Negative results in Jun 23

Risky - No result in last 6 months

Underperformed the market in the last 1 year

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 57 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

9.51

Return on Equity

-833.41%

Price to Book

1.52

Revenue and Profits:

Net Sales:

35 Cr

(Quarterly Results - Jun 2023)

Net Profit:

-16 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

-27.68%

4 Years

-66.81%

5 Years

-57.2%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Vivimed Labs Ltd witnessed a sharp decline on 11 Feb 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The share price fell by 4.9% to close at ₹6.80, just 1.18% above its 52-week low, signalling heightened investor anxiety and a deteriorating market sentiment towards the micro-cap pharmaceutical player.

Read full news article

Vivimed Labs Ltd Shares Plunge to Lower Circuit Amid Heavy Selling Pressure

Vivimed Labs Ltd, a micro-cap pharmaceutical stock, witnessed intense selling pressure on 10 Feb 2026, hitting its lower circuit limit and closing at ₹7.29, down 3.06% on the day. The stock underperformed its sector and the broader market, reflecting mounting investor concerns and unfilled supply at lower price levels.

Read full news article

Vivimed Labs Ltd Hits Upper Circuit Amid Strong Buying Pressure

Vivimed Labs Ltd (Stock ID: 612893) surged to hit its upper circuit limit on 09 Feb 2026, registering a maximum daily gain of 4.16% and closing at ₹7.51. This sharp rally was driven by robust buying interest, despite the stock trading below all major moving averages, signalling a potential trend reversal after a prolonged decline.

Read full news article

Announcements

Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)

09-Feb-2026 | Source : BSE

updates

Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

06-Feb-2026 | Source : BSE

Resignation of CFO

Updates

03-Feb-2026 | Source : BSE

disclosure under regulation 30

Corporate Actions

BOARD MEETING

13 Feb 2026

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-32.46%

EBIT Growth (5y)

-213.27%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

9.69

Net Debt to Equity (avg)

9.51

Sales to Capital Employed (avg)

0.64

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

14.80%

Institutional Holding

1.76%

ROCE (avg)

-8.47%

ROE (avg)

1.75%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.52

EV to EBIT

-1.51

EV to EBITDA

-2.43

EV to Capital Employed

1.05

EV to Sales

2.52

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.39%

ROE (Latest)

-833.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

14.799

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Bbr Projects Private Limited (11.45%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

65.18%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is -4.54% vs -33.57% in Mar 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is 94.14% vs -1,352.70% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.35",
          "val2": "37.03",
          "chgp": "-4.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.33",
          "val2": "-164.30",
          "chgp": "99.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.66",
          "val2": "8.52",
          "chgp": "25.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.58",
          "val2": "-265.99",
          "chgp": "94.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.93%",
          "val2": "-443.69%",
          "chgp": "442.76%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is -21.15% vs -72.46% in Mar 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -385.63% vs 13.05% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "187.10",
          "val2": "237.29",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-187.30",
          "val2": "-8.06",
          "chgp": "-2,223.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "35.90",
          "val2": "39.76",
          "chgp": "-9.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-328.53",
          "val2": "-67.65",
          "chgp": "-385.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-100.11%",
          "val2": "-3.40%",
          "chgp": "-96.71%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Jun'23

Mar'23

Change(%)

Net Sales

35.35

37.03

-4.54%

Operating Profit (PBDIT) excl Other Income

-0.33

-164.30

99.80%

Interest

10.66

8.52

25.12%

Exceptional Items

0.00

Consolidate Net Profit

-15.58

-265.99

94.14%

Operating Profit Margin (Excl OI)

-0.93%

-443.69%

442.76%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2023 is -4.54% vs -33.57% in Mar 2023

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2023 is 94.14% vs -1,352.70% in Mar 2023

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'23

Mar'23

Mar'22

Change(%)

Net Sales

187.10

237.29

-21.15%

Operating Profit (PBDIT) excl Other Income

-187.30

-8.06

-2,223.82%

Interest

35.90

39.76

-9.71%

Exceptional Items

0.00

Consolidate Net Profit

-328.53

-67.65

-385.63%

Operating Profit Margin (Excl OI)

-100.11%

-3.40%

-96.71%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2023 is -21.15% vs -72.46% in Mar 2022

Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -385.63% vs 13.05% in Mar 2022

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

Company Coordinates

Company Details

Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403

Tel: 91-8482-232045

http://www.vivimedlabs.com

yugandhar.kopparthi@vivimeslabs.com

Registrar Details

Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad